Tower Research Capital LLC TRC Purchases 7,612 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

Tower Research Capital LLC TRC grew its position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 530.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,046 shares of the company’s stock after buying an additional 7,612 shares during the quarter. Tower Research Capital LLC TRC’s holdings in PDS Biotechnology were worth $45,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in shares of PDS Biotechnology during the 3rd quarter worth approximately $52,000. SG Americas Securities LLC bought a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $52,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of PDS Biotechnology during the 3rd quarter worth approximately $56,000. Inspirion Wealth Advisors LLC lifted its position in shares of PDS Biotechnology by 1.7% during the 4th quarter. Inspirion Wealth Advisors LLC now owns 336,594 shares of the company’s stock worth $1,733,000 after buying an additional 5,720 shares in the last quarter. Finally, Corton Capital Inc. bought a new position in shares of PDS Biotechnology during the 3rd quarter worth approximately $112,000. Institutional investors own 26.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PDSB shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PDS Biotechnology in a report on Friday, January 12th. B. Riley reaffirmed a “buy” rating and issued a $11.00 price target (down previously from $14.00) on shares of PDS Biotechnology in a report on Thursday, March 28th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a report on Wednesday, March 27th. Finally, StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, March 16th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.33.

PDS Biotechnology Stock Performance

PDSB stock traded up $0.12 during midday trading on Thursday, reaching $3.73. 375,293 shares of the company’s stock traded hands, compared to its average volume of 846,047. The company has a 50-day moving average price of $4.28 and a two-hundred day moving average price of $4.80. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.75. PDS Biotechnology Co. has a 52 week low of $2.59 and a 52 week high of $10.27.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05. Sell-side analysts forecast that PDS Biotechnology Co. will post -1.55 earnings per share for the current year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.